Company News

ASC Therapeutics Announces Partnership With University of Massachusetts Medical School to Co-Develop Novel Gene Therapy for Maple Syrup Urine Disease

by

MILPITAS, Calif.–(BUSINESS WIRE)–ASC Therapeutics, a privately-held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies, today announced a partnership with the University of Massachusetts Medical School (UMMS) to co-develop a gene therapy for Maple Syrup Urine Disease (MSUD). “We look forward to working with the UMMS team led … Read more

Phase 1/2 Trial Set to Test ASC618, Gene Therapy for Hemophilia A

by

The U.S. Food and Drug Administration (FDA) has approved ASC Therapeutics’ request to open a clinical trial in the U.S. into the safety and early efficacy of ASC618, its second-generation gene therapy for hemophilia A. A Phase 1/2 trial (NCT04676048), set to start this month, will test the one-time therapy in up to 12 adults with moderate … Read more

ASC Therapeutics Receives IND Clearance From the U.S. Food and Drug Administration for ASC618 Second-Generation Gene Therapy for Hemophilia A

by

BusinessWire Transformational in-vivo AAV gene therapy for hemophilia A Efficiently biosynthesized and secreted bioengineered factor VIII Potentially leads to lower vector dose, reduced cost and extended durability MILPITAS, Calif.–ASC Therapeutics, a privately-held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies for hematologic and other rare disorders today … Read more

ASC Therapeutics “Advanced Genome Editing, Gene & Cell Therapy Platforms in the US and China” won the first prize

by

ASC Therapeutics “Advanced Genome Editing, Gene & Cell Therapy Platforms in the US and China” won the first prize of the “2021 Fifth Forum For New Drug R&D And Bio-Pharma Projects Roadshow” held on June 24, 2021 in Nanjing Biomedical Valley. Our CEO Ruhong Jiang, PhD, described our three platforms for second-generation gene therapy, CRISPR … Read more

ASC Therapeutics and Vigene Announce Long-Term Strategic Partnership for Gene Therapy Development and Manufacturing

by

MILPITAS, Calif.–(BUSINESS WIRE)–ASC Therapeutics (“ASC”), a privately-held gene therapy company focused on developing transformative gene-based medicines for serious diseases, announced today that it has entered into a long-term strategic manufacturing partnership with Vigene Biosciences (“Vigene”), a Maryland-based Contract Develop and Manufacturing Organization (CDMO). Vigene will provide ASC with access to GMP manufacturing including viral vectors … Read more

QUICK LINKS

Focus

NEWS

Investors

CONTACT US

Copyright © 2021 ASC Therapeutics